GLYBERA

This brand name is authorized in Estonia, Lithuania.

Active ingredients

The drug GLYBERA contains one active pharmaceutical ingredient (API):

1	Alipogene tiparvovec UNII 20OK4AFR4Y - ALIPOGENE TIPARVOVEC
	Alipogene tiparvovec contains the human lipoprotein lipase (LPL) gene variant LPLS447X in a vector. The human LPL gene variant LPLS447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle. Alipogene tiparvovec is injected as a one-time series into the muscle of the lower extremities where it is taken up by myocytes.
	Read more about Alipogene tiparvovec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GLYBERA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AX10	Alipogene tiparvovec	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1597338
LT	Valstybinė vaistų kontrolės tarnyba	1068258, 1077883